Emiliano Calvo
Emiliano Calvo
START Madrid-HM CIOCC
Adresse e-mail validée de startmadrid.com
Titre
Citée par
Citée par
Année
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ...
The Lancet Oncology 17 (7), 883-895, 2016
8892016
Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
J Tabernero, F Rojo, E Calvo, H Burris, I Judson, K Hazell, E Martinelli, ...
Journal of Clinical Oncology 26 (10), 1603-1610, 2008
5862008
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ...
The Lancet Oncology 17 (11), 1590-1598, 2016
4992016
Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer
MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ...
Cancer cell 33 (5), 853-861. e4, 2018
4732018
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
3422018
Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ...
Journal of clinical oncology 33 (30), 3401-3408, 2015
2832015
CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer
YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ...
Journal of Clinical Oncology 36 (28), 2836, 2018
2652018
Principles of oncologic pharmacotherapy
CH Takimoto, E Calvo
Cancer management: a multidisciplinary approach 11, 1-9, 2008
2542008
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
DA White, P Camus, M Endo, B Escudier, E Calvo, H Akaza, H Uemura, ...
American journal of respiratory and critical care medicine 182 (3), 396-403, 2010
2252010
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
J Rodon, MA Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ...
Clinical Cancer Research 21 (3), 553-560, 2015
1762015
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
E Calvo, J Baselga
Journal of Clinical Oncology 24 (14), 2158-2163, 2006
1692006
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer
J Cortes, J Rodriguez, JM Aramendia, E Salgado, A Gurpide, ...
Oncology 64 (1), 28-35, 2003
1682003
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion …
AJ Gonzalez-Martin, E Calvo, I Bover, MJ Rubio, A Arcusa, A Casado, ...
Annals of oncology 16 (5), 749-755, 2005
1542005
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor …
E Calvo, B Escudier, RJ Motzer, S Oudard, TE Hutson, C Porta, ...
European Journal of Cancer 48 (3), 333-339, 2012
1492012
The association between asthma control, health care costs, and quality of life in France and Spain
M Doz, C Chouaid, L Com-Ruelle, E Calvo, M Brosa, J Robert, ...
BMC pulmonary medicine 13 (1), 1-10, 2013
1302013
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
1122011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid …
F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ...
Clinical Cancer Research 17 (19), 6304-6312, 2011
1122011
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
E Calvo, AW Tolcher, LA Hammond, A Patnaik, JS de Bono, IA Eiseman, ...
Clinical Cancer Research 10 (21), 7112-7120, 2004
1102004
Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label …
I Brana, A Calles, PM LoRusso, LK Yee, TA Puchalski, S Seetharam, ...
Targeted oncology 10 (1), 111-123, 2015
1082015
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
M Aapro, F Andre, K Blackwell, E Calvo, M Jahanzeb, K Papazisis, ...
Annals of oncology 25 (4), 763-773, 2014
932014
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20